Goldman Sachs’s Connect Biopharma Holdings CNTB Stock Holding History

Goldman Sachs’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-29,833	Closed	-$78.2K	–	6622
2026 Q1	$78.2K	Buy	+29,833	New	+$77.8K	﹤0.01%	6239
2022 Q4	–	Sell	-13,497	Closed	-$17K	–	6011
2022 Q3	$17K	Sell	13,497 -5,956	-31%	-$7.16K	﹤0.01%	5961
2022 Q2	$17K	Buy	19,453 +172	+0.9%	+$253	﹤0.01%	6199
2022 Q1	$58K	Buy	19,281 +7,490	+64%	+$31.6K	﹤0.01%	6237
2021 Q4	$61K	Buy	+11,791	New	+$131K	﹤0.01%	6230

Other funds holding CNTB

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return

DMKJ

David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Goldman Sachs's CNTB Position: Q2 2026 in Review

Goldman Sachs sold out of Connect Biopharma Holdings (CNTB) in Q2 2026, closing a stake of 29,833 shares — an estimated $78.2K sold.

Goldman Sachs first reported a position in CNTB in Q4 2021 and held it in 5 quarters. The position peaked at $78.2K in Q1 2026. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

Goldman Sachs reported no remaining Connect Biopharma Holdings position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 29,833 Connect Biopharma Holdings shares in Q2 2026, an estimated $78.2K.
Goldman Sachs first reported a position in Connect Biopharma Holdings in Q4 2021 and held it in 5 quarters.
Goldman Sachs's Connect Biopharma Holdings position peaked at $78.2K in Q1 2026.
56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.